Drugs Made In America Acquisition Corp. (DMAAR)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
DMAAR Chart
People also search for
Drugs Made In America Acquisition Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Bulldog Investors Bulldog Investors LLP | 130,264 | $21,227.29 | $13,026.4 | -$8,200.89 | -38.63% |
| BO Brian Oliveira Clear Street Group Inc. | 625,435 | $135,969.76 | $62,543.5 | -$73,426.26 | -54% |
Drugs Made In America Acquisition Corp. (DMAAR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Drugs Made In America Acquisition Corp. ever had a stock split?
Drugs Made In America Acquisition Corp. Profile
| Industrial Conglomerates Industry | Industrials Sector | Roger Bendelac CEO | NASDAQ (NMS) Exchange | KYG2847J1123 ISIN |
| US Country | 2 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Drugs Made In America Acquisition Corp. is a blank check company established for the purpose of facilitating business combinations. This exempt entity specializes in executing mergers, share exchanges, asset acquisitions, and other similar financial agreements with one or more existing businesses. Founded on May 23, 2024, the company operates from its headquarters located in Fort Lauderdale, Florida. With a focus on the pharmaceutical industry, the firm is dedicated to identifying and investing in businesses that align with its vision of enhancing domestic drug production and innovation.
Products and Services
- Blank Check Company Operations:
This service involves raising capital through initial public offerings (IPOs) to acquire existing firms in the drugs and pharmaceuticals sector. This capital can be utilized for various forms of business combinations that cater to the strategic needs of the target businesses.
- Mergers and Acquisitions:
The company offers strategic assistance in merging with or acquiring other pharmaceutical entities, optimizing operational efficiencies, and expanding market reach in the competitive landscape of drug manufacturing.
- Recapitalization Services:
Facilitating recapitalization opportunities that can involve restructuring a company's financial framework to improve liquidity, reduce debt, or provide funds for future growth in the pharmaceutical industry.
- Share Purchase Agreements:
Engaging in share purchase arrangements that enable investment in promising pharmaceutical companies, providing them with necessary capital and support to stimulate development and progress.
- Reorganization Strategies:
Advising and implementing effective organizational changes within target companies to enhance their operational capabilities and adapt strategically to industry shifts.
